Check out what we’ve been up to and where can we connect!
August 4, 2020
FHI Clinical is pleased to announce our partnership with Tiziana Life Sciences to expedite clinical development of TZLS-501, a novel fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb), for the treatment of COVID-19 (SARS-CoV-2) patients.
July 23, 2020
Claudia Christian of FHI Clinical recently spoke with the editor for Outsourcing-Pharma about the clinical services that FHI Clinical is providing to the Frederick National Laboratory for Cancer Research for the ongoing ACTT adaptive study allowing investigation of putative therapeutics for the treatment of COVID-19 in hospitalized adults.
July 22, 2020
Phase I/II studies to evaluate human placental hematopoietic stem cell–derived natural killer (NK) cell therapy to treat COVID-19 in hospitalized adults are currently ongoing as part of our partnership with the Infectious Disease Research Institute (IDRI).
July 14, 2020
FHI Clinical Inc. announced that it has a subcontract with the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide clinical operations services for the Adaptive COVID-19 Treatment Trial (ACTT). ACTT is an adaptive study to allow investigation of putative therapeutics, for the treatment of COVID-19 in hospitalized adults.
June 25, 2020
Several months ago, FHI Clinical began recruiting scientific and technological experts to join our newly formed panel of Scientific Advisory Experts, which was created to promote best practices, build alliances and spur innovation in the clinical trials research field. Today, we are pleased to announce that we have appointed six new members.
June 12, 2020
Claudia Christian, Senior VP, Clinical Operations, recently spoke with Seth Gulledge, writer for the Research Triangle Park, North Carolina-based Triangle Business Journal, about how the COVID-19 pandemic has disrupted the traditional model for clinical trials. This has prompted CROs around the Triangle to rapidly integrate virtual trial models to speed up clinical research and push COVID-19 vaccines and therapies to market.
August 11, 2020
Patient safety and data integrity remain of utmost importance as CROs navigate shifting regulatory guidelines, reevaluate their existing strategies and reprioritize IT projects. Register to learn how the pandemic has transformed the clinical trial landscape, the operational shifts that are needed within CROs, the technologies that have been most impactful and some of the obstacles and barriers to transformation.
Missed the webinar? View the recording for an inside perspective regarding proper planning and implementation of process workflows and unified technology platforms to allow study teams to manage better quality data, more efficiently, and gain critical insights in support of clinical development programs.
Missed the webinar? View the recording to hear industry infectious disease experts discuss the importance of quality historical, testing and tracking data for timely, coordinated responses to outbreaks.
An FHI Clinical representative will be present at the Medical Technology Enterprise Consortium’s (MTEC) 5th Annual Membership Meeting in Houston, TX, March 4-5, 2020. Set up a meeting to discuss FHI Clinical’s global operational experience.
FHI Clinical representatives will be present at the 11th Annual SCOPE Summit in Orlando, FL, February 18-21, 2020. Set up a meeting to discuss FHI Clinical’s operational experience around the world.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA